Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 1.04
ZMH's Cash to Debt is ranked higher than
64% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. ZMH: 1.04 )
ZMH' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: 1.04

Equity to Asset 0.68
ZMH's Equity to Asset is ranked higher than
74% of the 447 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ZMH: 0.68 )
ZMH' s 10-Year Equity to Asset Range
Min: 0.03   Max: 0.84
Current: 0.68

0.03
0.84
Interest Coverage 14.77
ZMH's Interest Coverage is ranked higher than
55% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 231.38 vs. ZMH: 14.77 )
ZMH' s 10-Year Interest Coverage Range
Min: 14.37   Max: 9999.99
Current: 14.77

14.37
9999.99
F-Score: 7
Z-Score: 6.18
M-Score: -2.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 23.96
ZMH's Operating margin (%) is ranked higher than
96% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. ZMH: 23.96 )
ZMH' s 10-Year Operating margin (%) Range
Min: 21.07   Max: 33.34
Current: 23.96

21.07
33.34
Net-margin (%) 17.04
ZMH's Net-margin (%) is ranked higher than
93% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. ZMH: 17.04 )
ZMH' s 10-Year Net-margin (%) Range
Min: 12.71   Max: 23.87
Current: 17.04

12.71
23.87
ROE (%) 12.63
ZMH's ROE (%) is ranked higher than
87% of the 445 Companies
in the Global Medical Devices industry.

( Industry Median: 5.20 vs. ZMH: 12.63 )
ZMH' s 10-Year ROE (%) Range
Min: 10.46   Max: 115.87
Current: 12.63

10.46
115.87
ROA (%) 8.39
ZMH's ROA (%) is ranked higher than
88% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. ZMH: 8.39 )
ZMH' s 10-Year ROA (%) Range
Min: 7.56   Max: 32.15
Current: 8.39

7.56
32.15
ROC (Joel Greenblatt) (%) 40.16
ZMH's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. ZMH: 40.16 )
ZMH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 35.96   Max: 119.58
Current: 40.16

35.96
119.58
Revenue Growth (3Y)(%) 8.60
ZMH's Revenue Growth (3Y)(%) is ranked higher than
82% of the 341 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. ZMH: 8.60 )
ZMH' s 10-Year Revenue Growth (3Y)(%) Range
Min: 8.6   Max: 25.6
Current: 8.6

8.6
25.6
EBITDA Growth (3Y)(%) 9.40
ZMH's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. ZMH: 9.40 )
ZMH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 3.1   Max: 39.6
Current: 9.4

3.1
39.6
EPS Growth (3Y)(%) 14.30
ZMH's EPS Growth (3Y)(%) is ranked higher than
85% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. ZMH: 14.30 )
ZMH' s 10-Year EPS Growth (3Y)(%) Range
Min: -3.1   Max: 41.7
Current: 14.3

-3.1
41.7
» ZMH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ZMH Guru Trades in Q4 2013

RS Investment Management 49,400 sh (New)
Pioneer Investments 312,886 sh (+20.55%)
John Rogers 928,760 sh (+1.99%)
Jean-Marie Eveillard 1,632 sh (unchged)
John Hussman Sold Out
Jim Simons Sold Out
Jeff Auxier 97,802 sh (-0.05%)
Mario Gabelli 315,502 sh (-0.58%)
Bill Frels 663,084 sh (-0.97%)
PRIMECAP Management 457,300 sh (-1.36%)
Ken Fisher 178,645 sh (-1.59%)
Scott Black 128,824 sh (-3.6%)
Vanguard Health Care Fund 2,146,200 sh (-6.48%)
Robert Olstein 71,000 sh (-6.58%)
Jeremy Grantham 2,287,917 sh (-9.9%)
HOTCHKIS & WILEY 1,521,304 sh (-16.69%)
Steven Cohen 314,523 sh (-19.69%)
Ray Dalio 6,792 sh (-35.26%)
Paul Tudor Jones 183,700 sh (-40.63%)
Private Capital 158,125 sh (-45.62%)
Joel Greenblatt 2,691 sh (-51.51%)
David Dreman 340 sh (-72.34%)
» More
Q1 2014

ZMH Guru Trades in Q1 2014

Jim Simons 355,760 sh (New)
Joel Greenblatt 45,597 sh (+1594.43%)
David Dreman 1,531 sh (+350.29%)
RS Investment Management 63,100 sh (+27.73%)
Pioneer Investments 348,679 sh (+11.44%)
HOTCHKIS & WILEY 1,599,304 sh (+5.13%)
John Rogers 952,482 sh (+2.55%)
Vanguard Health Care Fund 2,146,200 sh (unchged)
Jean-Marie Eveillard 1,632 sh (unchged)
Ray Dalio Sold Out
PRIMECAP Management 457,200 sh (-0.02%)
Bill Frels 661,009 sh (-0.31%)
Private Capital 156,250 sh (-1.19%)
Scott Black 126,647 sh (-1.69%)
Mario Gabelli 308,402 sh (-2.25%)
Jeff Auxier 95,527 sh (-2.33%)
Ken Fisher 171,570 sh (-3.96%)
Robert Olstein 67,000 sh (-5.63%)
Jeremy Grantham 1,732,793 sh (-24.26%)
Steven Cohen 212,136 sh (-32.55%)
Paul Tudor Jones 13,878 sh (-92.45%)
» More
Q2 2014

ZMH Guru Trades in Q2 2014

Andreas Halvorsen 603,193 sh (New)
Jim Simons 760,200 sh (+113.68%)
Robert Olstein 87,000 sh (+29.85%)
David Dreman 1,666 sh (+8.82%)
RS Investment Management 63,250 sh (+0.24%)
Steven Cohen 378,709 sh (unchged)
Scott Black Sold Out
Mario Gabelli 308,121 sh (-0.09%)
Ken Fisher 170,061 sh (-0.88%)
PRIMECAP Management 450,100 sh (-1.55%)
Jeff Auxier 93,417 sh (-2.21%)
Private Capital 151,365 sh (-3.13%)
Bill Frels 637,320 sh (-3.58%)
HOTCHKIS & WILEY 1,536,345 sh (-3.94%)
Paul Tudor Jones 12,470 sh (-10.15%)
Pioneer Investments 295,991 sh (-15.11%)
Vanguard Health Care Fund 1,779,800 sh (-17.07%)
John Rogers 753,063 sh (-20.94%)
Jean-Marie Eveillard 1,122 sh (-31.25%)
Jeremy Grantham 1,054,694 sh (-39.13%)
Joel Greenblatt 4,631 sh (-89.84%)
» More
Q3 2014

ZMH Guru Trades in Q3 2014

Scott Black 86,763 sh (New)
Louis Moore Bacon 155,000 sh (New)
Paul Tudor Jones 412,347 sh (+3206.71%)
John Rogers 1,047,358 sh (+39.08%)
Robert Olstein 108,000 sh (+24.14%)
Jeremy Grantham 1,117,893 sh (+5.99%)
David Dreman 1,721 sh (+3.3%)
RS Investment Management 64,515 sh (+2%)
Mario Gabelli 313,486 sh (+1.74%)
Ken Fisher 170,119 sh (+0.03%)
Andreas Halvorsen Sold Out
Jeff Auxier 93,267 sh (-0.16%)
PRIMECAP Management 449,204 sh (-0.2%)
Bill Frels 630,696 sh (-1.04%)
Pioneer Investments 289,618 sh (-2.15%)
HOTCHKIS & WILEY 1,470,345 sh (-4.3%)
Joel Greenblatt 4,418 sh (-4.6%)
Private Capital 135,920 sh (-10.2%)
Vanguard Health Care Fund 1,589,200 sh (-10.71%)
Jean-Marie Eveillard 873 sh (-22.19%)
Steven Cohen 261,800 sh (-30.87%)
Jim Simons 387,600 sh (-49.01%)
» More
» Details

Insider Trades

Latest Guru Trades with ZMH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Scott Black 2014-09-30 New Buy1.2%$95.31 - $105.23 $ 114.9114%86763
John Rogers 2014-09-30 Add 39.08%0.39%$95.31 - $105.23 $ 114.9114%1047358
Andreas Halvorsen 2014-09-30 Sold Out 0.27%$95.31 - $105.23 $ 114.9114%0
Robert Olstein 2014-09-30 Add 24.14%0.27%$95.31 - $105.23 $ 114.9114%108000
Private Capital 2014-09-30 Reduce -10.2%0.18%$95.31 - $105.23 $ 114.9114%135920
Jean-Marie Eveillard 2014-09-30 Reduce -22.19%$95.31 - $105.23 $ 114.9114%873
Scott Black 2014-06-30 Sold Out 1.3%$90.99 - $107.2 $ 114.9114%0
Robert Olstein 2014-06-30 Add 29.85%0.28%$90.99 - $107.2 $ 114.9114%87000
Andreas Halvorsen 2014-06-30 New Buy0.27%$90.99 - $107.2 $ 114.9114%603193
John Rogers 2014-06-30 Reduce -20.94%0.23%$90.99 - $107.2 $ 114.9114%753063
Joel Greenblatt 2014-06-30 Reduce -89.84%0.06%$90.99 - $107.2 $ 114.9114%4631
Jean-Marie Eveillard 2014-06-30 Reduce -31.25%$90.99 - $107.2 $ 114.9114%1122
Joel Greenblatt 2014-03-31 Add 1594.43%0.06%$90.87 - $98.35 $ 114.9121%45597
David Dreman 2014-03-31 Add 350.29%0.01%$90.87 - $98.35 $ 114.9121%1531
Ray Dalio 2014-03-31 Sold Out 0.01%$90.87 - $98.35 $ 114.9121%0
Private Capital 2013-12-31 Reduce -45.62%1%$82.66 - $93.43 $ 114.9129%158125
John Hussman 2013-12-31 Sold Out 0.25%$82.66 - $93.43 $ 114.9129%0
HOTCHKIS & WILEY 2013-12-31 Reduce -16.69%0.12%$82.66 - $93.43 $ 114.9129%1521304
David Dreman 2013-12-31 Reduce -72.34%0.01%$82.66 - $93.43 $ 114.9129%340
Joel Greenblatt 2013-12-31 Reduce -51.51%0.01%$82.66 - $93.43 $ 114.9129%2691
Ray Dalio 2013-12-31 Reduce -35.26%$82.66 - $93.43 $ 114.9129%6792
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 24.80
ZMH's P/E(ttm) is ranked higher than
89% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 85.90 vs. ZMH: 24.80 )
ZMH' s 10-Year P/E(ttm) Range
Min: 9.08   Max: 61.06
Current: 24.8

9.08
61.06
P/B 2.97
ZMH's P/B is ranked higher than
76% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.88 vs. ZMH: 2.97 )
ZMH' s 10-Year P/B Range
Min: 1.31   Max: 6.26
Current: 2.97

1.31
6.26
P/S 4.21
ZMH's P/S is ranked higher than
66% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.41 vs. ZMH: 4.21 )
ZMH' s 10-Year P/S Range
Min: 1.82   Max: 8.95
Current: 4.21

1.82
8.95
PFCF 28.73
ZMH's PFCF is ranked higher than
88% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ZMH: 28.73 )
ZMH' s 10-Year PFCF Range
Min: 9.54   Max: 50.48
Current: 28.73

9.54
50.48
EV-to-EBIT 17.30
ZMH's EV-to-EBIT is ranked higher than
90% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 64.69 vs. ZMH: 17.30 )
ZMH' s 10-Year EV-to-EBIT Range
Min: 6.8   Max: 45.8
Current: 17.3

6.8
45.8
PEG 3.02
ZMH's PEG is ranked higher than
92% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ZMH: 3.02 )
ZMH' s 10-Year PEG Range
Min: 0.42   Max: 5.43
Current: 3.02

0.42
5.43
Shiller P/E 28.69
ZMH's Shiller P/E is ranked higher than
92% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ZMH: 28.69 )
ZMH' s 10-Year Shiller P/E Range
Min: 10.71   Max: 39.22
Current: 28.69

10.71
39.22
Current Ratio 3.96
ZMH's Current Ratio is ranked higher than
80% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. ZMH: 3.96 )
ZMH' s 10-Year Current Ratio Range
Min: 1.14   Max: 5.09
Current: 3.96

1.14
5.09
Quick Ratio 2.89
ZMH's Quick Ratio is ranked higher than
79% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. ZMH: 2.89 )
ZMH' s 10-Year Quick Ratio Range
Min: 0.71   Max: 3.69
Current: 2.89

0.71
3.69

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.75
ZMH's Dividend Yield is ranked lower than
72% of the 185 Companies
in the Global Medical Devices industry.

( Industry Median: 1.39 vs. ZMH: 0.75 )
ZMH' s 10-Year Dividend Yield Range
Min: 0.28   Max: 1.1
Current: 0.75

0.28
1.1
Dividend Payout 0.19
ZMH's Dividend Payout is ranked higher than
97% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ZMH: 0.19 )
ZMH' s 10-Year Dividend Payout Range
Min: 0.15   Max: 0.23
Current: 0.19

0.15
0.23
Yield on cost (5-Year) 0.80
ZMH's Yield on cost (5-Year) is ranked lower than
71% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 1.59 vs. ZMH: 0.80 )
ZMH' s 10-Year Yield on cost (5-Year) Range
Min: 0.28   Max: 1.1
Current: 0.8

0.28
1.1
Share Buyback Rate 5.10
ZMH's Share Buyback Rate is ranked higher than
97% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: -1.10 vs. ZMH: 5.10 )
ZMH' s 10-Year Share Buyback Rate Range
Min: 6.6   Max: -8.4
Current: 5.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.74
ZMH's Price/Tangible Book is ranked higher than
72% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.71 vs. ZMH: 5.74 )
ZMH' s 10-Year Price/Tangible Book Range
Min: 4.19   Max: 233.33
Current: 5.74

4.19
233.33
Price/DCF (Projected) 1.37
ZMH's Price/DCF (Projected) is ranked higher than
94% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ZMH: 1.37 )
ZMH' s 10-Year Price/DCF (Projected) Range
Min: 0.58   Max: 2.12
Current: 1.37

0.58
2.12
Price/Median PS Value 1.18
ZMH's Price/Median PS Value is ranked higher than
73% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. ZMH: 1.18 )
ZMH' s 10-Year Price/Median PS Value Range
Min: 0.57   Max: 2.63
Current: 1.18

0.57
2.63
Price/Peter Lynch Fair Value 3.36
ZMH's Price/Peter Lynch Fair Value is ranked higher than
95% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ZMH: 3.36 )
ZMH' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.66   Max: 3.1
Current: 3.36

0.66
3.1
Price/Graham Number 2.49
ZMH's Price/Graham Number is ranked higher than
85% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ZMH: 2.49 )
ZMH' s 10-Year Price/Graham Number Range
Min: 1.36   Max: 22.07
Current: 2.49

1.36
22.07
Earnings Yield (Greenblatt) 5.80
ZMH's Earnings Yield (Greenblatt) is ranked higher than
90% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ZMH: 5.80 )
ZMH' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.2   Max: 14.7
Current: 5.8

2.2
14.7
Forward Rate of Return (Yacktman) 11.26
ZMH's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 5.50 vs. ZMH: 11.26 )
ZMH' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 9   Max: 45.7
Current: 11.26

9
45.7

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, STJ, EW » details
Traded in other countries:ZMH.Switzerland, ZIM.Germany, 0QQD.UK,
Zimmer Holdings Inc was incorporated in 2001. The Company designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, biologics, dental implants and related surgical products. It also provides other healthcare related services. Its products include orthopaedic reconstructive implants, spinal and trauma devices, biologics, dental implants and related surgical products. Its orthopaedic reconstructive devices restore function lost due to disease or trauma in joints such as knees, hips, shoulders and elbows. Its dental reconstructive implants restore function and aesthetics in patients who have lost teeth due to trauma or disease. Its spinal devices are utilized by orthopaedic surgeons and neurosurgeons in the treatment of degenerative diseases, deformities and trauma in all regions of the spine. Its trauma products are devices used to reattach or stabilize damaged bone and tissue to support the body's natural healing process. The Company has its operations in more than 25 countries and markets its products in more than 100 countries. The Company operates in a single industry but have three reportable geographic segments, the Americas, Europe and Asia Pacific. The Americas, which is comprised of the U.S. and includes other North, Central and South American markets; Europe, which is comprised of Europe and includes the Middle East and African markets; and Asia Pacific, which is comprised of Japan and includes other Asian and Pacific markets. The Company's customers include orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers and, in their capacity as agents, healthcare purchasing organizations or buying groups. It markets and sells its products through three channels; direct to healthcare institutions, such as hospitals, referred to as direct channel accounts; through stocking distributors and healthcare dealers; and directly to dental practices and dental laboratories. The Company operates distribution facilities domestically in Warsaw, Indiana; Southaven, Mississippi; and Carlsbad, California and internationally in Australia, Austria, Belgium, Canada, the Czech Republic, China, Finland, France, Germany, Hong Kong, India, Italy, Japan, Korea, Malaysia, the Netherlands, New Zealand, Portugal, Russia, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand and the United Kingdom. The Company competes with the DePuy Synthes Companies of Johnson & Johnson, Stryker Corporation, Biomet, Inc., and Smith & Nephew plc. It protects its proprietary rights through a variety of methods, including confidentiality agreements and proprietary information agreements with vendors, employees, consultants and others who may have access to proprietary information. The Company is subject to government regulation in the countries in which it conducts business.
» More Articles for ZMH

Headlines

Articles On GuruFocus.com
I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
Weekly 52-Week Highs Highlight: TGT, THI, TRI, ZMH Nov 17 2014 
Medical Technology Company Offers Investment Opportunity Sep 25 2014 
Simon Properties Reports Insider Trades Mar 13 2013 
Stryker Corporation (SYK) Dividend Stock Analysis Jan 11 2013 
These 5 Stocks Are Most Hated by Big Investors Nov 07 2012 
52-Week High Companies: ZMH, CVX, V, REGN, DFS Sep 10 2012 
5 Healthcare Stocks You Should Know About Mar 31 2012 
5 Healthcare Stocks to Consider for 2012 Mar 27 2012 
Edward Owens’ Vanguard Health Care Fund Biggest Buys in Fourth Quarter Jan 30 2012 

More From Other Websites
Final Glance: Medical Devices companies Dec 19 2014
U.S. appeals court cuts damages Zimmer must pay Stryker Dec 19 2014
Midday Glance: Medical Devices companies Dec 19 2014
Early Glance: Medical Devices companies Dec 19 2014
Dec 15, 2014 Zimmer Holdings, Inc. Announces Quarterly Dividend for Fourth Quarter of 2014 Dec 15 2014
Zimmer Holdings, Inc. Announces Quarterly Dividend for Fourth Quarter of 2014 Dec 15 2014
Dec 12, 2014 Zimmer Holdings Names Michael Farrell to Board of Directors Dec 12 2014
ZIMMER HOLDINGS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Dec 12 2014
Zimmer Holdings Names Michael Farrell to Board of Directors Dec 12 2014
APAC Joint Replacement Market to Reach $6.4 Billion by 2020 Dec 10 2014
EU mergers and takeovers (Dec 4) Dec 04 2014
I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014
Dec 4, 2014 Zimmer Provides Update on the European Commission Review Process Relating to the Pending... Dec 04 2014
ZIMMER HOLDINGS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 04 2014
Zimmer Provides Update on the European Commission Review Process Relating to the Pending Merger with... Dec 04 2014
Zimmer Holdings to Present at 26th Annual Piper Jaffray Healthcare Conference Nov 20 2014
Synovasure® PJI Test Earns Certification To Clear Way For European Sales Nov 19 2014
Nov 18, 2014 Zimmer Provides Update on the European Commission Review Process Relating to the... Nov 18 2014
ZIMMER HOLDINGS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 18 2014
Zimmer Provides Update on the European Commission Review Process Relating to the Pending Merger with... Nov 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK